Tuesday, Mar 16, 1993

Genentech Files Complaint with International Trade Commission to Enforce Growth Hormone Patents

South San Francisco, Calif. -- March 16, 1993 --

Genentech, Inc. (NYSE: GNE) today announced that it has filed a complaint with the United States International Trade Commission (ITC) asserting three of its United States patents for the development and manufacture of its human growth hormone products -- known commercially as Protropin® (somatrem for injection) and Nutropin® (somatropin for injection) -against Novo-Nordisk A/S, BioTechnology General Corporation and their respective agents.

Protropin has been on the U.S. market since 1985 for the treatment of growth hormone deficiency in children. Nutropin, the company's other human growth hormone product, is currently under development for the same indication and under active clinical review for other indications such as short stature associated with Turner's Syndrome and chronic renal insufficiency.

The ITC complaint states that Bio-Technology General Corporation (BTG) of New York has infringed upon U.S. Patent Nos. 4,342,832 and 4,601,980. The complaint further states that Novo-Nordisk (Novo) of Bagsvaerd, Denmark has infringed on these patents and one other, U.S. Patent No. 4,366,246. The patents all relate to processes vital to the commercial production of human growth hormone.

Pursuant to various parts of section 337 of the Tariff Act of 1930, Genentech is seeking the following: 1 ) an immediate investigation into unfair methods of competition based upon patent infringement; and 2) an order that would force Novo and BTG to cease and desist from infringing Genentech's patents directed to processes for the manufacture of human growth hormone.

Genentech, Inc., is a biotechnology company involved in the research, development and manufacture of human pharmaceuticals that meet significant unmet medical needs. The company remains committed to providing its products to patients who need them regardless of their ability to pay. In fact, since the creation of its Uninsured Patients Program in 1985, Genentech has supplied more than $90 million worth of free Protropin to growth-deficient children in need.

Genentech has headquarters in South San Francisco and is traded over the New York and Pacific Stock Exchanges under the symbol GNE.

# # #